Patents Assigned to Xoma Technologies, Ltd.
  • IL-1? binding antibodies and fragments thereof
    Patent number: 7943121
    Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: May 17, 2011
    Assignee: XOMA Technology Ltd.
    Inventors: Linda Masat, Mary Haak-Frendscho, Arnold H. Horwitz, Gang Chen, Marina Roell
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 7943344
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: May 17, 2011
    Assignees: AVEO Pharmaceuticals, Inc., XOMA Technology Ltd.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Novel Modulators
    Publication number: 20110076284
    Abstract: Antibodies that modulate insulin receptor signaling are provided.
    Type: Application
    Filed: September 24, 2010
    Publication date: March 31, 2011
    Applicant: XOMA TECHNOLOGY LTD.
    Inventors: John Corbin, Mark L. White, Susan R. Watson, Vinay Bhaskar
  • FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING
    Publication number: 20110076279
    Abstract: Vascular endothelial growth factor (VEGF) overexpression is associated with a variety of conditions involving aberrant angiogenesis. Disclosed herein are fully human antibodies that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling Based on their ability to inhibit VEGF signaling, the antibodies disclosed herein may be used to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
    Type: Application
    Filed: October 22, 2007
    Publication date: March 31, 2011
    Applicants: SCHERING CORPORATION, XOMA TECHNOLOGY LTD.
    Inventors: Sumant Ramachandra, Walter Robert Bishop, Linda Masat, Chao Bai Huang
  • LIBRARIES, ARRAYS AND THEIR USES FOR TARGETED AFFINITY ENHANCEMENT
    Publication number: 20110039722
    Abstract: The present disclosure relates to methods and materials for enhancing the binding affinity of an antibody by means of generating a library or an array of targeted amino acid changes (e.g., mutations) at one or more positions in an antibody variable domain. The present disclosure relates to libraries or arrays and their uses for enhancing antibody affinity. The present disclosure relates to methods and materials for mutagenesis, including for the generation of novel or improved antibody variable domains and libraries or arrays of mutant antibody variable domains or nucleic acids encoding such mutant or modified variable domains.
    Type: Application
    Filed: December 31, 2008
    Publication date: February 17, 2011
    Applicant: XOMA TECHNOLOGY LTD.
    Inventors: Toshihiko Takeuchi, Gary Studnicka
  • METHODS FOR THE TREATMENT OF IL-1BETA RELATED DISEASES
    Publication number: 20110038859
    Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.
    Type: Application
    Filed: April 9, 2010
    Publication date: February 17, 2011
    Applicant: XOMA Technology Ltd.
    Inventors: Alan M. Solinger, Patrick J. Scannon, Robert J. Bauer, David Alleva
  • PRLR-specific antibody and uses thereof
    Patent number: 7867493
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: January 11, 2011
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
  • CARDIOVASCULAR RELATED USES OF IL-1BETA ANTIBODIES AND BINDING FRAGMENTS THEREOF
    Publication number: 20100316651
    Abstract: Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1? binding molecules (e.g., IL-1? binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease.
    Type: Application
    Filed: May 28, 2010
    Publication date: December 16, 2010
    Applicant: XOMA TECHNOLOGY LTD.
    Inventors: PATRICK J. SCANNON, ALAN M. SOLINGER, JEFFREY D. FELDSTEIN
  • METHODS FOR THE TREATMENT OF IL-1BETA RELATED DISEASES
    Publication number: 20100303807
    Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.
    Type: Application
    Filed: February 23, 2010
    Publication date: December 2, 2010
    Applicant: XOMA TECHNOLOGY LTD.
    Inventors: Alan M. Solinger, Patrick J. Scannon, Robert J. Bauer, David Alleva
  • Method of treating an IL-1 related cancer
    Patent number: 7829094
    Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: November 9, 2010
    Assignee: Xoma Technology Ltd.
    Inventors: Linda Masat, Mary Haak-Frendscho, Arnold H. Horwitz, Gang Chen, Marina Roell
  • Method of treating an IL-1 related autoimmune disease or condition
    Patent number: 7829093
    Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: November 9, 2010
    Assignee: Xoma Technology Ltd.
    Inventors: Linda Masat, Mary Haak-Frendscho, Arnold H. Horwitz, Gang Chen, Marina Roell
  • Methods and materials for expression of a recombinant protein
    Patent number: 7794976
    Abstract: Recombinant expression vectors are provided comprising a 3?UTR of a light chain and an Epstein-Barr virus origin of replication. Also provided are host cells comprising such vectors and methods of producing recombinant protein with such vectors. Additional methods of producing a recombinant protein involve contacting cells with a first and second vector, each of which encode a different polypeptide chain, and wherein the second vector is present in an amount which is about 1.5 to 2.5 times as much as that of the first vector. Cells also can be transfected with a recombinant transient expression vector encoding a protein and are cultured in a medium in a membrane-enhanced culturing vessel to produce recombinant protein.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: September 14, 2010
    Assignee: XOMA Technology Ltd.
    Inventors: Masahisa Handa, Arnold H. Horwitz, Robyn Cotter, Eddie Batista
  • NOVEL TRIPLE TAG SEQUENCE AND METHODS OF USE THEREOF
    Publication number: 20100184612
    Abstract: The present disclosure relates to novel triple tag sequences that may comprise a 6× histidine tag, a c-myc tag and a V5 tag. The present disclosure also provides polynucleotides, proteins, vectors and host cells that comprise the triple tag sequence of the present disclosure, including libraries of such polynucleotides, proteins, vectors and host cells. The novel triple tag sequences of the present disclosure may be used in phage display vectors and phage libraries and in methods for detection, screening, capture, purification, quantitation, and/or recovery of proteins of interest to which they are linked. Proteins of interest include antibodies such as single chain antibodies, single chain antibodies, and Fab fragments of antibodies or peptides such as non-antibody peptides.
    Type: Application
    Filed: October 2, 2009
    Publication date: July 22, 2010
    Applicant: XOMA TECHNOLOGY, LTD.
    Inventors: Isaac Rondon, Marina Roell, Daniel Bedinger
  • Methods for recombinant peptide production
    Patent number: 7749731
    Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: July 6, 2010
    Assignee: XOMA Technology Ltd.
    Inventors: Marc D. Better, Patrick D. Gavit
  • IL1-? Binding antibodies and fragments thereof
    Patent number: 7744865
    Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 8 and SEQ ID NO: 9, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: June 29, 2010
    Assignee: Xoma Technology Ltd.
    Inventors: Linda Masat, Mary Haak-Frendscho, Arnold H. Horwitz, Gang Chen, Marina Roell
  • IL-1? binding antibodies and binding fragments thereof
    Patent number: 7744866
    Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 26 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: June 29, 2010
    Assignee: XOMA Technology Ltd.
    Inventors: Linda Masat, Mary Haak-Frendscho, Arnold H. Horwitz, Gang Chen, Marina Roell
  • Soluble Human M-CSF Receptor and Uses Thereof
    Publication number: 20100099123
    Abstract: Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: December 21, 2006
    Publication date: April 22, 2010
    Applicants: Novartis AG, Xoma Technology Ltd.
    Inventors: Cheng Liu, Maja Deuter-Reinhard, John Kunich, Michael Kavanaugh
  • M-CSF-Specific Monoclonal Antibody and Uses Thereof
    Publication number: 20100092464
    Abstract: M-CSF-specific RX1-based or RX-I derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in or remodeling in a subject afflicted with an osteoblastic or osteolytic disease.
    Type: Application
    Filed: July 27, 2006
    Publication date: April 15, 2010
    Applicants: Novartis AG, XOMA Technology Ltd.
    Inventors: William M. Kavanaugh, Lea Auckerman, Victoria Sung
  • Methods for the treatment of IL-1? related diseases
    Patent number: 7695718
    Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: April 13, 2010
    Assignee: Xoma Technology Ltd.
    Inventors: Alan M. Solinger, Patrick J. Scannon, Robert J. Bauer
  • Method of treating an IL-1 related inflammatory disease or condition
    Patent number: 7695717
    Abstract: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1? binding antibody or IL-1? binding fragment thereof. An IL-1? binding antibody or IL-1? binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1? binding polypeptide is provided. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: April 13, 2010
    Assignee: XOMA Technology Ltd.
    Inventors: Linda Masat, Mary Haak-Frendscho, Gang Chen, Arnold Horwitz, Marina Roell